(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (JJ chemical) (NN shift) (NNS changes)))) (VP (VBZ reveals) (NP (NP (DT the) (NN binding) (NNS modes)) (PP (IN of) (NP (NP (JJ isoindolinone) (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN MDM2-p53) (NN interaction)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (NN method)) (PP (IN for) (S (VP (VBG defining) (NP (NP (DT the) (NN binding) (NNS modes)) (PP (IN of) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (ADJP (RB structurally) (JJ related)) (NN isoindolinone) (NNS inhibitors))) (PP (IN of) (NP (DT the) (NN MDM2-p53) (NN interaction)))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN approach)) (VP (VBZ derives) (NP (NP (DT the) (NP (NN location)) (CC and) (NP (NN orientation))) (PP (IN of) (NP (NP (NN isoindolinone) (NN binding)) (, ,) (VP (VBN based) (PP (IN on) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS patterns)) (PP (IN of) (NP (NP (NP (NN magnitude)) (CC and) (NP (NN direction))) (PP (IN of) (NP (NP (JJ chemical) (NN shift) (NNS perturbations)) (PP (IN for) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN MDM2-p53) (NN interaction))))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN MDM2-p53) (NN complex)) (VP (VBZ is) (NP (NP (DT an) (JJ attractive) (NN target)) (PP (IN for) (NP (NP (JJ therapeutic) (NN intervention)) (PP (IN in) (NP (NN cancer) (NNS cells))) (PP (IN with) (NP (JJ intact) (NN tumor) (NN suppressor) (NN p53)))))) (, ,) (SBAR (IN as) (S (NP (PRP it)) (VP (VBZ offers) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (VBG releasing) (NN p53)))) (PP (IN by) (S (VP (VBG blocking) (NP (DT the) (NN MDM2-p53) (NN binding) (NN site)) (PP (IN with) (NP (NP (DT a) (JJ small) (NN molecule) (NN antagonist)) (S (VP (TO to) (VP (VB promote) (NP (NN apoptosis))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Isoindolinones)) (VP (VBP are) (NP (NP (DT a) (JJ novel) (NN class)) (PP (IN of) (NP (NP (NNS MDM2-antagonists)) (PP (IN of) (NP (JJ moderate) (NN affinity))))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB still)) (VP (VBP require) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (ADJP (RBR more) (JJ potent)) (NNS candidates)) (PP (IN for) (NP (JJ clinical) (NNS applications)))))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (NP (DT the) (NN applicability)) (PP (IN of) (NP (JJ conventional) (JJ structural) (NNS methods))) (PP (TO to) (NP (DT this) (NN system)))) (VP (VBZ is) (VP (VBN limited) (PP (IN by) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ fundamental) (NNS factors))))))))) (, ,) (NP (NP (DT the) (NN exploitation)) (PP (IN of) (NP (NP (DT the) (NN information)) (VP (VBN contained) (PP (IN in) (NP (JJ chemical) (NN shift) (NNS perturbations))))))) (VP (VBZ has) (VP (VBN offered) (NP (NP (DT a) (JJ useful) (NN route)) (PP (TO to) (S (VP (VBG obtaining) (NP (JJ structural) (NN information)) (S (VP (TO to) (VP (VB guide) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (ADJP (RBR more) (JJ potent)) (NNS compounds)))))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (CD 12) (ADJP (RB structurally) (JJ related)) (NNS isoindolinones))))) (, ,) (NP (DT the) (NN data)) (VP (VBZ suggests) (NP (NP (CD 4) (JJ different) (NNS orientations)) (PP (IN of) (NP (NN binding))) (, ,) (VP (VBN caused) (PP (IN by) (NP (NP (JJ subtle) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ chemical) (NN structure)) (PP (IN of) (NP (DT the) (NNS inhibitors))))))))))) (. .)))
